(Reuters) -Novo Nordisk and Pfizer ( PFE ) have revised their bids for Metsera ( MTSR ), the obesity drug developer said on Tuesday.

Novo's revised offer brings the deal value to about $10 billion, while Pfizer ( PFE ) is now willing to shell out $8.1 billion.

The revised bids come as both companies are engaged in a public dispute to acquire Metsera ( MTSR ).

Pfizer ( PFE ) has filed two lawsuits against Metsera ( MTSR ), its board, and Novo Nordisk.

The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's ( PFE ) merger agreement and seeks to bypass antitrust review. Pfizer ( PFE ) is asking a court to block Metsera ( MTSR ) from terminating the deal, with a hearing set for later on Tuesday.

As per Novo's new offer, Metsera ( MTSR ) is also eligible to receive an additional $24.00 per share in cash, up from $22.50, based on development and regulatory approval milestones.